SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...

(Reuters) - Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for ...

The stronger outlook follows mixed results from other major medical device makers in the latest quarter, after both Abbott ...

Edwards Lifesciences (NYSE:EW) today announced 10-year results from the COMMENCE aortic trial supporting its proprietary ...

Analysts expect Edwards to post earnings of 73 cents per share on revenue of $1.6 billion, representing year-over-year growth of 17.6% and 13.48% respectively. That would mark a sequential improvement ...

Edwards Lifesciences Corp (EW) reports a robust 12.7% sales growth in Q1 2026, raises full-year guidance, and showcases significant advancements in TAVR and TMTT segments.

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...